There is a strong chance of technical success in the pivotal Phase 3 trial due to exceptional efficacy data for treating third-line non-small cell lung cancer (NSCLC). The data suggest promising outcomes for patients, with high effectiveness rates in the study. This news indicates a significant advancement in medical research and treatment, potentially offering new hope to those affected by NSCLC.